Xilio Therapeutics (XLO) Share-based Compensation (2020 - 2026)
Xilio Therapeutics (XLO) posted Share-based Compensation of $2.2 million for Q1 2026, down 24.54% sequentially from $2.9 million in Q4 2025, and up 44.04% YoY from $1.5 million in Q1 2025.
Xilio Therapeutics (XLO) Share-based Compensation (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Share-based Compensation for 7 years, with the latest figure at $2.2 million in Q1 2026.
- Quarterly Share-based Compensation rose 44.04% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (up 24.1% YoY) and the FY2025 annual result came in at $11.0 million, up 50.68% from the prior year.
- Share-based Compensation retreated to $2.2 million in Q1 2026 per XLO's latest filing, from $2.9 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.9 million in Q4 2025 and troughed at $1.1 million in Q3 2025.
- A 5-year average of $1.8 million and a median of $1.8 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation jumped 170.36% in 2022, then plunged 33.55% in 2023.
- Over 5 years, Share-based Compensation stood at $1.8 million in 2022, then rose by 6.34% to $1.9 million in 2023, then retreated by 21.45% to $1.5 million in 2024, then jumped by 93.27% to $2.9 million in 2025, then decreased by 24.54% to $2.2 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.2 million, $2.9 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 1.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.60 Mn |
| Jun 30, 2026 | 1.60 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Dec 31, 2025 | 2.93 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.12 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Mar 31, 2025 | 1.54 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | 1.51 Mn |
| Mar 31, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.83 Mn |